Journal of Investigational Allergology and Clinical Immunology最新文献_第7页

Regular Allergen Exposure During Oral Immunotherapy Alters the Transcriptomic Innate Immune Response After Cellular Restimulation in Children With Egg Allergy. 口服免疫治疗期间的常规过敏原暴露改变了鸡蛋过敏儿童细胞再刺激后的转录组先天免疫反应。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-05-02 DOI: 10.18176/jiaci.1079

Victoria I Hinkkanen, Terhi Savinko, Kati Palosuo, Harri Alenius, Mika J Mäkelä, Piia Karisola

{"title":"Regular Allergen Exposure During Oral Immunotherapy Alters the Transcriptomic Innate Immune Response After Cellular Restimulation in Children With Egg Allergy.","authors":"Victoria I Hinkkanen, Terhi Savinko, Kati Palosuo, Harri Alenius, Mika J Mäkelä, Piia Karisola","doi":"10.18176/jiaci.1079","DOIUrl":"10.18176/jiaci.1079","url":null,"abstract":"Background and objective: Oral immunotherapy (OIT) is a promising treatment for food allergies. However, the molecular mechanisms leading to desensitization remain unknown. Objective: To better understand the immunological mechanisms and transcriptional changes underlying desensitization to food allergens during OIT.Methods: Our cohort consisted of 40 Finnish children with egg allergy who underwent OIT. Peripheral blood mononuclear cells (PBMCs) were collected at 0, 3, and 8 months of therapy and stimulated with an egg allergen extract. Differentially expressed genes (DEGs) were identified based on quantile-normalized and batch-corrected microarray data using a linear model. Gene enrichment and Pearson correlation analyses were conducted.Results: After 8 months of therapy, 45% of patients were fully desensitized and 55% partially desensitized. Stimulation with egg yielded 49 DEGs at 0 months, 723 DEGs at 3 months, and 759 DEGs at 8 months in PBMCs after comparison with unstimulated controls. At 8 months of OIT, allergen stimulation led to down-regulation of proinflammatory pathways, as well as IL-4 and IL-13 signaling. At baseline, the immune response in the fully desensitized group was more reactive than in the partially desensitized group.Conclusions: During OIT, general immune activity is increased, especially the number of down-regulated genes, suggesting active immune suppression. Transcriptomic profiles differ between fully and partially desensitized patients, with a notably more reactive immune response in the fully desensitized group at baseline. Innate immunity seems to play a significant role in the development of desensitization during OIT.","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"132-142"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IgE-Mediated Hypersensitivity to Olaparib Diagnosed and Monitored With the Basophil Activation Test. 用嗜碱性粒细胞激活试验诊断和监测ige介导的奥拉帕尼超敏反应。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2026-02-09 DOI: 10.18176/jiaci.1140

Ana Morales-Hidalgo, Alicia Gómez-López, Jose A Cañas, Marcela Valverde-Monge, Carlos Villalobos-Vilda, Victoria Del Pozo Abejón, Joaquín Sastre

引用次数: 0

Adrenaline: A Lifeline for Rapid Drug Desensitization in Hypersensitive Patients. 肾上腺素：过敏患者快速药物脱敏的生命线。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-04-25 DOI: 10.18176/jiaci.1075

Johana Gil-Serrano, Paula Galvan-Blasco, Javier Pereira-Gonzalez, Arnau Salvany-Pijuan, Mercedes Gonzalez Di-Paolo, Mar Guilarte, Olga Luengo, Anna Sala-Cunill, Victoria Cardona, Moisés Labrador-Horrillo

{"title":"Adrenaline: A Lifeline for Rapid Drug Desensitization in Hypersensitive Patients.","authors":"Johana Gil-Serrano, Paula Galvan-Blasco, Javier Pereira-Gonzalez, Arnau Salvany-Pijuan, Mercedes Gonzalez Di-Paolo, Mar Guilarte, Olga Luengo, Anna Sala-Cunill, Victoria Cardona, Moisés Labrador-Horrillo","doi":"10.18176/jiaci.1075","DOIUrl":"10.18176/jiaci.1075","url":null,"abstract":"Background and objective: Chemotherapeutic agents (CMTs) and monoclonal antibodies (mAbs) are common causes of drug allergy, which is often managed using rapid drug desensitization (RDD). Despite its effectiveness, RDD can be hampered by severe breakthrough reactions (BTRs), potentially leading to failure of the procedure. Objective: To evaluate the usefulness and safety of adrenaline infusion (AI) as an adjuvant during RDD in patients who experience severe drug hypersensitivity reaction (DHR) during standard desensitization protocols.Methods: Retrospective observational study, analyzing data from patients who underwent RDD to CMTs or mAbs in a tertiary hospital from January 2015 to June 2024. We included patients who required AI to safely achieve RDD after a severe initial DHR or failure of a standard RDD protocol due to repeated DHRs. Comorbidities, adrenaline doses, and adverse events (AEs) were assessed.Results: RDD with AI was administered in 42 patients. Of these, 77% (n=32) were women, and the mean age was 57 years. The most frequently involved drugs were platinum salts (58%), mAbs (26%), and taxanes (14%). A total of 151 RDDs were performed with AI. Skin tests were positive in 69% of patients. The most frequent initial BTR (65%) was moderate or severe anaphylaxis. The most common AEs induced by AI were tremor (14%) and tachycardia (7%), which resolved after reducing the AI infusion rate. The median (IQR) cumulative dose of adrenaline administered throughout the RDD procedure was 0.76 mg (0.4-1.2mg), with a median infusion rate of 8 mL/h (4- 15ml/h), and median maximum AI rate of 3.33 μg/min (2-5.3 μg/min).Conclusions: AI is a useful and safe therapeutic tool for selected high-risk desensitization procedures, mitigating severe DHR with mostly minor AEs.","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"113-120"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Position Statement on Autonomous Adrenaline Administration for Anaphylaxis by Nursing Professionals in Spain: Joint Recommendations From the Anaphylaxis and Nursing Committees of the Spanish Society of Allergy and Clinical Immunology (SEAIC). 西班牙护理专业人员对过敏反应自主肾上腺素管理的立场声明：西班牙过敏和临床免疫学学会（SEAIC）过敏反应和护理委员会的联合建议。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-12-15 DOI: 10.18176/jiaci.1138

Gustavo-Jorge Molina-Molina, Dolores López, Filip Skrabski, Valentín López-Carrasco, Pilar Hernández, Victoria Cardona

引用次数: 0

Dupilumab in Eosinophilic Gastrointestinal Disorders With Extraesophageal Involvement: A Pediatric Case Series and Systematic Review. Dupilumab治疗食管外受累的嗜酸性胃肠道疾病：儿科病例系列和系统回顾。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-11-05 DOI: 10.18176/jiaci.1098

Camille Braun, Kelly Grzywacz, Dorothée Dal Soglio, Eric Drouin, Marie E Chartier, Martha Dirks, Laurence Chapuy, Kathryn Samaan, François Graham, Louis Paradis, Anne Des Roches, Philippe Bégin

{"title":"Dupilumab in Eosinophilic Gastrointestinal Disorders With Extraesophageal Involvement: A Pediatric Case Series and Systematic Review.","authors":"Camille Braun, Kelly Grzywacz, Dorothée Dal Soglio, Eric Drouin, Marie E Chartier, Martha Dirks, Laurence Chapuy, Kathryn Samaan, François Graham, Louis Paradis, Anne Des Roches, Philippe Bégin","doi":"10.18176/jiaci.1098","DOIUrl":"10.18176/jiaci.1098","url":null,"abstract":"Dupilumab has proven effective in the treatment of eosinophilic esophagitis (EoE) in randomized controlled trials. Its efficacy in other, less common and generally more severe eosinophilic gastrointestinal disorders (EGIDs) is scientifically plausible, although it has not been studied to date. Our objective was to describe published and our experience on the empirical use of dupilumab in patients affected by EGIDs with extraesophageal involvement. We retrospectively analyzed the medical charts of children diagnosed with extraesophageal EGIDs treated with dupilumab at our tertiary medical center. The Medline, Embase, and Cochrane databases were searched up to January 2025 for articles describing the use of dupilumab in patients with diagnosed or suspected extraesophageal EGID. Our cohort included 8 patients with a clinical and histological diagnosis of EGID and extraesophageal involvement. All of them had recurrent gastrointestinal symptoms refractory to standard treatments. Three patients had growth retardation. In all patients, symptoms and macroscopic and histological abnormalities, including eosinophilic infiltration, quickly improved after initiation of dupilumab. The systematic review identified 11 case reports (n=29 patients) of pediatric and adult patients with extraesophageal EGIDs treated with dupilumab. All 11 reports described significant clinical and histological improvement following therapy. Clinical experience suggests that dupilumab is effective in treating pediatric EGIDs with extraesophageal features. Given the rarity and high morbidity of these disorders, dupilumab could be considered a reasonable option while waiting for high-quality evidence from ongoing randomized controlled trials.","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"100-112"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing the Allergenic Relevance of Vespula alascensis Venom: Implications for Venom Immunotherapy. 评估黄脉蛇毒液的致敏性：对毒液免疫治疗的影响。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-11-21 DOI: 10.18176/jiaci.1108

Benjamin O Slusarenko, Klara F Borrmann, Claudia Knappe, Jonathan Vogel, Benjamin Schnautz, Stéphanie Kler, Tilo Biedermann, Knut Brockow, Ulf Darsow, Thalia Carreno Velazquez, Elisabetta Francescato, Simon J Hewings, Matthias F Kramer, Matthew D Heath, Gunnar Dittmar, Christiane Hilger, Ralph S Peters, Carsten B Schmidt-Weber, Bernadette Eberlein, Simon Blank

{"title":"Assessing the Allergenic Relevance of Vespula alascensis Venom: Implications for Venom Immunotherapy.","authors":"Benjamin O Slusarenko, Klara F Borrmann, Claudia Knappe, Jonathan Vogel, Benjamin Schnautz, Stéphanie Kler, Tilo Biedermann, Knut Brockow, Ulf Darsow, Thalia Carreno Velazquez, Elisabetta Francescato, Simon J Hewings, Matthias F Kramer, Matthew D Heath, Gunnar Dittmar, Christiane Hilger, Ralph S Peters, Carsten B Schmidt-Weber, Bernadette Eberlein, Simon Blank","doi":"10.18176/jiaci.1108","DOIUrl":"10.18176/jiaci.1108","url":null,"abstract":"Background and objective: Venom immunotherapy (VIT) is an effective treatment for yellow jacket venom (YJV) allergy. It is often based on mixtures of venom from different species. Recent taxonomic re-evaluation has revealed that widely used VIT preparations contain venom from Vespula alascensis, a North American species, rather than venom from the Palearctic Vespula vulgaris. Objective: To assess the allergenic relevance of V alascensis venom for European patients and evaluate its suitability for inclusion in VIT preparations.Methods: The ability of V alascensis and V vulgaris venom to activate effector cells from YJV-allergic patients from Germany was compared using the basophil activation test. Patients' sIgE reactivity was assessed using ELISA, inhibition ELISA, CAP inhibition, and Western blot. Proteomic analysis of the venoms was also conducted.Results: Basophil activation tests showed highly similar activation profiles for V alascensis and V vulgaris venoms. Moreover, ELISA and inhibition analyses revealed comparable overall sIgE reactivity for both venoms. In contrast, Western blot analysis demonstrated similar sIgE profiles for antigen 5 allergens, although phospholipase A1 allergens were differentially detected. Proteomic analysis revealed no differences in the major allergens of the 2 venoms.Conclusion: This study demonstrates the functional similarity between V alascensis and V vulgaris venoms in allergic responses. Moreover, it highlights the clinical relevance of V alascensis for YJV-sensitized European patients and supports its inclusion in YJV VIT preparations in Europe.","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"121-131"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145589826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of Specific Venom Immunotherapy to Vespa velutina nigrithorax Through Controlled Re-sting With Asian Hornet. 亚洲大黄蜂控制针刺特异性毒液免疫治疗羽绒小黄蜂黑胸的疗效验证。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-12-19 DOI: 10.18176/jiaci.1134

Cristina Galán Gimeno, Ángel Arrien de Lecea, Javier Sánchez de Vicente, Mónica Pérez Escalera, Aritza Segurola Azcarate, Ignacio Jáuregui Presa

引用次数: 0

Metal Hypersensitivity-Related Refractory Coronary In-Stent Restenosis Treated With Prednisone and Dupilumab: A Case Report. 强的松联合杜匹单抗治疗金属超敏性冠脉支架内再狭窄1例

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-12-09 DOI: 10.18176/jiaci.1131

Yiyun Pang, Qian Wang, Lei Jia, Rui Tang

引用次数: 0

Rethinking Penicillin Allergy Pathways: Insights from a 5-Year Audit at Barts Health NHS Trust. 重新思考青霉素过敏途径：从巴茨健康NHS信托5年审计的见解。

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-12-16 DOI: 10.18176/jiaci.1127

Maria L Quiñones Obando, Rodanthe Nixon, Anand Sundaralingam, Bryan N Fernandes, Fawzia R Ali, Ricardo Madrigal-Burgaleta

引用次数: 0

Acquired Hemophilia A Following Omalizumab Treatment in a Patient With Chronic Spontaneous Urticaria. 慢性自发性荨麻疹患者接受Omalizumab治疗后获得性血友病A

IF 4.8 3区医学

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-04-14 Epub Date: 2025-12-09 DOI: 10.18176/jiaci.1144

M Teresa Dordal-Culla, Blanca Andrés-López, Dario Alexandre Duminy, Gemma Rocamora Blanch, Laura López-Andreoni, M Dolores Rodríguez-Cumplido, Ramon Lleonart Bellfill

引用次数: 0